查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1462671

靜脈血栓栓塞症治療的全球市場預測（截至 2030 年）：按產品、疾病狀態、最終用戶和地區進行分析

Venous Thromboembolism Treatment Market Forecasts to 2030 - Global Analysis By Product, Disease Indication, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

2023年全球靜脈血栓栓塞症治療市場規模為12.8874億美元，預計預測期內年複合成長率為10.7%，2030年達到26.2543億美元。靜脈血栓栓塞症(VTE) 治療通常涉及多方面策略，以防止新血栓形成、降低併發症風險並促進血栓溶解。抗凝血劑經常用於即時治療，以阻止血栓和栓塞的形成，因為它們可能導致危及生命的後果，例如肺動脈栓塞。血栓的治療方法各不相同，並且根據血栓的位置和嚴重程度而有所不同，從口服抗凝血劑到靜脈注射藥物（如肝素）。

據美國心臟協會稱，靜脈血栓栓塞症(VTE) 是一項重大的公共衛生風險，僅在美國每年估計就有 60 萬例病例。

提高對 VTE 的認知

由於醫學教育、意識提升宣傳活動和患者支持計劃方面加大努力，靜脈血栓栓塞症(VTE) 已被廣泛認為是重要的醫療保健問題。識別 VTE 危險因子、症狀和適當的診斷技術正在成為醫療保健專業培訓的重要組成部分。此外，隨著患者對 VTE 的了解越來越多，他們意識到早期介入並儘快就醫的重要性。此外，醫學協會和組織傳播指南和建議支持宣傳宣傳活動，並確保 VTE 始終處於臨床實踐和公共衛生議程的前沿。

高昂的治療費用

治療 VTE 的相關費用，包括抗凝血劑、診斷測試、住院和治療後護理，給患者、付款人和醫療保健系統帶來了巨大的經濟負擔。儘管新型口服抗凝血劑（NOAC）比Warfarin需要更少的監測，但它們通常很昂貴，限制了它們的可用性，特別是在資源有限的環境中。此外，某些患者群體，例如患有高風險血栓性疾病或復發性靜脈血栓栓塞的患者，需要更長時間持續抗凝血治療，這進一步增加了治療成本。

增加直介面服抗凝血劑（DOAC）的使用

直接凝血酶抑制劑和 Xa 因子抑制劑是市場上快速成長的直介面服抗凝血劑 (DOAC) 的兩個例子。快速起效、可預測的藥物動力學和降低藥物交互作用的風險只是 DOAC 相對於傳統抗凝血治療的一些優勢。隨著更多臨床資料證明 DOAC 在治療急性 VTE、延長血栓預防和預防次發性VTE 的安全性和有效性，預計 DOAC 的使用將會增加。此外，正在進行的研究旨在透過改善給藥方案、探索新的適應症和開發逆轉劑來解決出血併發症，進一步提高 DOAC 治療 VTE 的有效性。

抗藥性增加

抗凝血治療VTE的有效性因抗藥性的出現而受到嚴重威脅。影響藥物代謝的遺傳變異、藥物標靶的後天變異、不遵守治療方法是導致抗凝血劑抗藥性的一些因素。抗藥性的產生會降低抗凝血劑的治療效果，導致治療失敗並增加血栓事件的風險。此外，對於已經產生抗凝血抵抗的患者來說，缺乏替代治療選擇，使得充分治療 VTE 變得更加困難。

COVID-19 的影響

靜脈血栓栓塞症(VTE) 治療市場動態受到 COVID-19 爆發的影響。儘管由於對嚴重COVID-19 病例血栓併發症的認知提高，抗凝血治療的需求增加，但醫療服務、選擇性手術和患者照護途徑的變化正在導致 VTE 診斷和開始治療延遲。 VTE 治療的處方模式和市場動態也受到資源限制、供應鏈中斷和不斷變化的醫療保健優先事項的影響。此外，製藥公司和靜脈血栓栓塞治療提供者還面臨著大流行病經濟影響帶來的額外挑戰，包括病患保險覆蓋範圍減少和醫療保健預算限制。

預計抗凝血劑領域在預測期內將是最大的

用抗凝血劑治療靜脈血栓栓塞症（VTE）的細分市場佔據最大的市場佔有率。抗凝血劑對於 VTE 的治療至關重要，可預防血栓形成、栓塞和血栓事件復發。抗凝血劑有多種劑型，患者可以根據自身特徵和臨床需求選擇治療方法。此外，抗凝血劑包括腸胃外藥物和口服藥物。建議急性治療 VTE，並透過抗凝血治療長期預防血栓栓塞併發症。

預計門診醫療中心細分市場在預測期內年複合成長率最高

當涉及靜脈血栓栓塞症（VTE）治療市場時，門診醫療中心領域通常表現出最高的年複合成長率。門診醫療中心提供各種醫療狀況（包括 VTE）的診斷、治療和管理的門診服務。此外，向門診護理的轉變是由多種因素推動的，包括醫療成本的上漲、微創手術的發展以及優先考慮患者便利性和成本效益的基於價值的護理模式的採用。

佔比最大的地區：

由於完善的醫療保健系統、高昂的醫療成本、先進的診斷工具以及肥胖、久坐的生活方式和人口老齡化等 VTE 危險因素的高患病率，北美地區佔據了最大的佔有率。領先產業參與者的存在、持續的研發計劃以及有利的報銷做法進一步推動了北美市場的擴張。此外，在 VTE 的預防、診斷和治療方面的積極努力，以及患者和醫療保健專業人員意識的提高，使該地區在 VTE 治療市場上處於世界領先地位。

年複合成長率最高的地區：

歐洲是靜脈血栓栓塞症（VTE）治療市場年複合成長率最高的地區。許多因素導致了 VTE 病例的成長和發病率的增加，包括日益常見的危險因素，例如老化、肥胖和久坐的生活方式。此外，治療方法、診斷方法和醫療基礎設施的改進提高了我們控制 VTE 的能力。此外，強力的研發努力、醫療改革和支持性法規結構正在促進創新並支持市場擴張。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球靜脈血栓栓塞症治療市場：依產品

  • 血栓清除裝置
  • 下腔靜脈濾器
    • 可回收過濾器
    • 永久過濾器
  • 絲襪
  • 抗凝血物
  • 壓縮幫浦
  • 其他產品

第6章全球靜脈血栓栓塞症治療市場：依疾病狀況

  • 深層靜脈栓塞症
  • 肺動脈栓塞
  • 其他醫療狀況

第7章全球靜脈血栓栓塞症治療市場：依最終使用者分類

  • 醫院和診所
  • 門診治療中心
  • 導管實驗室
  • 其他最終用戶

第8章全球靜脈血栓栓塞症治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第9章 主要進展

  • 協議、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Mitsubishi Tanabe Pharma Corporation
  • Cardinal Health, Inc.
  • Koninklijke Philips NV
  • Boston Scientific Corporation
  • Johnson & Johnson
  • Stryker Corporation
  • Sanofi
  • Abbott Laboratories
  • Leo Pharma A/S
  • Novartis AG
  • Pfizer Inc.
  • Mylan NV
  • Argon Medical Devices, Inc.
  • Medtronic plc
  • Teva Pharmaceutical Industries Ltd.
  • LifeTech Scientific Corporation
  • Bayer AG
  • CSL Limited
  • Biogenics Inc.
Product Code: SMRC25722

According to Stratistics MRC, the Global Venous Thromboembolism Treatment Market is accounted for $1288.74 million in 2023 and is expected to reach $2625.43 million by 2030 growing at a CAGR of 10.7% during the forecast period. In order to prevent new clot formation, lower the risk of complications, and encourage clot dissolution, venous thromboembolism (VTE) treatment usually entails a multifaceted strategy. Anticoagulant drugs, which can cause life-threatening outcomes like pulmonary embolism, are frequently used in immediate management to stop clot extension and embolization. Treatments for blood clots can vary, ranging from oral anticoagulants to intravenous drugs like heparin, depending on their location and severity.

According to the American Heart Association, venous thromboembolism (VTE) poses a significant risk to public health, with an estimated incidence of up to 600,000 cases per year in the United States alone.

Market Dynamics:

Driver:

Raising awareness of VTE

Venous thromboembolism (VTE) is now more widely acknowledged as a serious healthcare concern as a result of increased efforts in medical education, awareness campaigns, and patient advocacy programs. The identification of VTE risk factors, symptoms, and suitable diagnostic techniques is becoming a more important part of healthcare professionals training. Additionally, as patients gain more knowledge about VTE, they realize how critical it is to intervene early and seek medical attention as soon as possible. Further boosting awareness campaigns and guaranteeing that VTE stays a top concern in clinical practice and public health agendas is the distribution of guidelines and recommendations by medical societies and organizations.

Restraint:

Exorbitant treatment expenses

The expenses associated with treating VTE, such as anticoagulant drugs, diagnostic exams, hospital stays, and post-treatment care, can place a heavy financial strain on patients, insurers, and healthcare systems. Despite having fewer monitoring requirements than warfarin, novel oral anticoagulants (NOACs) are frequently more expensive, which limits their accessibility, particularly in settings with limited resources. Furthermore, treatment costs are further increased by the requirement for extended-duration anticoagulation therapy in specific patient populations, such as those with high-risk thrombophilic conditions or recurrent VTE.

Opportunity:

Increasing use of direct oral anticoagulants (DOACs)

Direct thrombin inhibitors and factor Xa inhibitors are two examples of direct oral anticoagulants (DOACs) that are seeing rapid growth in the market. The rapid onset of action, predictable pharmacokinetics, and reduced risk of drug interactions are just a few benefits that DOACs have over conventional anticoagulant therapies. It is anticipated that the use of DOACs will rise as more clinical data demonstrates their safety and effectiveness in treating acute VTE, prolonging thromboprophylaxis, and preventing secondary VTE. Additionally, ongoing studies aim to further improve the effectiveness of DOACs in the treatment of VTE by refining dosage regimens, investigating novel indications, and creating reversal medications to address bleeding complications.

Threat:

Rise in medication resistance

The efficacy of anticoagulant therapies in the treatment of VTE is seriously threatened by the emergence of drug resistance. Genetic variations affecting drug metabolism, acquired mutations in drug targets, and non-adherence to treatment regimens are some of the factors that can lead to resistance to anticoagulants. Resistance development could reduce anticoagulant drugs therapeutic effectiveness, which would result in treatment failure and a higher risk of thrombotic events. Moreover, the difficulty of adequately treating VTE is further compounded by the scarcity of alternative treatment options for patients who have developed anticoagulant resistance.

Covid-19 Impact:

Venous thromboembolism (VTE) treatment market dynamics have been affected by the COVID-19 pandemic. Delays in VTE diagnosis and treatment initiation have been caused by changes in healthcare delivery, elective procedures, and patient care pathways, even as the demand for anticoagulant therapies has increased due to the increased awareness of thrombotic complications in severe COVID-19 cases. The prescribing patterns and market dynamics for VTE treatments have also been impacted by resource limitations, disruptions in the supply chain, and changes in healthcare priorities. Additionally, pharmaceutical companies and providers of VTE treatment face additional challenges due to the economic effects of the pandemic, such as reduced patient insurance coverage and healthcare budget constraints.

The Anticoagulant Medications segment is expected to be the largest during the forecast period

The segment that treats venous thromboembolism (VTE) with anticoagulant medications holds the largest market share. In order to prevent clot formation, embolization, and recurrent thrombotic events, anticoagulants are essential to the management of VTE. Patients can choose their treatment according to their individual characteristics and clinical needs because these medications come in a variety of formulations. Furthermore, these include parenteral agents and oral anticoagulants. It is advised to treat VTE acutely and prevent thromboembolic complications over the long term with anticoagulant therapy.

The Ambulatory Care Centers segment is expected to have the highest CAGR during the forecast period

When it comes to the Venous Thromboembolism (VTE) Treatment Market, the ambulatory care center segment usually has the highest CAGR. Outpatient services for the diagnosis, treatment, and management of a range of medical conditions, including VTE, are provided by ambulatory care centers. Moreover, the growing inclination towards ambulatory care can be attributed to various factors, including rising healthcare costs, developments in minimally invasive procedures, and the adoption of value-based care models that prioritize patient convenience and cost effectiveness.

Region with largest share:

North America usually has the largest share, due to factors, like well-established healthcare system, high healthcare costs, sophisticated diagnostic tools, and a high prevalence of VTE risk factors like obesity, sedentary lifestyles, and aging populations, are responsible for this dominance. Further supporting the market expansion in North America is the existence of significant industry players, continuous R&D initiatives, and advantageous reimbursement practices. Additionally, due in part to the region's proactive approach to VTE prevention, diagnosis, and treatment, as well as rising patient and healthcare professional awareness, it leads the world in the VTE treatment market.

Region with highest CAGR:

Europe is the region that frequently exhibits the highest CAGR in the market for treatments for venous thromboembolism (VTE). A number of factors, including the aging population, obesity, and sedentary lifestyles, which are risk factors that are becoming more common, are responsible for this growth and the increased incidence of VTE cases. Furthermore, improvements in treatment modalities, diagnostic methods, and healthcare infrastructure improve the area's ability to control VTE. In addition, robust R&D efforts, healthcare reforms, and supportive regulatory frameworks encourage innovation and propel market expansion.

Key players in the market

Some of the key players in Venous Thromboembolism Treatment market include Mitsubishi Tanabe Pharma Corporation, Cardinal Health, Inc., Koninklijke Philips N.V., Boston Scientific Corporation, Johnson & Johnson, Stryker Corporation, Sanofi, Abbott Laboratories, Leo Pharma A/S, Novartis AG, Pfizer Inc., Mylan N.V., Argon Medical Devices, Inc., Medtronic plc, Teva Pharmaceutical Industries Ltd., LifeTech Scientific Corporation, Bayer AG, CSL Limited and Biogenics Inc.

Key Developments:

In January 2024, Cardinal Health Inc. announced an agreement to buy Specialty Networks for $1.2 billion in cash, as the drug distributor and medical products maker looks to enhance its data analytics capabilities. The company said the acquisition expands its offering in therapeutic areas and increases its data and research opportunities with biopharmaceutical manufacturers.

In January 2024, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Axonics, Inc., a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The purchase price is $71 in cash per share, reflecting an equity value of approximately $3.7 billion and an enterprise value of approximately $3.4 billion.

In January 2024, Johnson & Johnson has reached tentative agreement to resolve talc baby powder claims with more than 40 states, the world's biggest maker of health care products confirmed. That progress includes an agreement in principle that the company reached with a consortium of 43 State Attorneys Generals to resolve their talc claims.

Products Covered:

  • Thrombectomy Devices
  • Inferior Vena Cava Filters
  • Stockings
  • Anticoagulant Medications
  • Compression Pumps
  • Other Products

Disease Indications Covered:

  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Other Disease Indications

End Users Covered:

  • Hospitals and Clinics
  • Ambulatory Care Centers
  • Catheterization Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Venous Thromboembolism Treatment Market, By Product

  • 5.1 Introduction
  • 5.2 Thrombectomy Devices
  • 5.3 Inferior Vena Cava Filters
    • 5.3.1 Retrievable Filters
    • 5.3.2 Permanent Filters
  • 5.4 Stockings
  • 5.5 Anticoagulant Medications
  • 5.6 Compression Pumps
  • 5.7 Other Products

6 Global Venous Thromboembolism Treatment Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Deep Vein Thrombosis
  • 6.3 Pulmonary Embolism
  • 6.4 Other Disease Indications

7 Global Venous Thromboembolism Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals and Clinics
  • 7.3 Ambulatory Care Centers
  • 7.4 Catheterization Laboratories
  • 7.5 Other End Users

8 Global Venous Thromboembolism Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Mitsubishi Tanabe Pharma Corporation
  • 10.2 Cardinal Health, Inc.
  • 10.3 Koninklijke Philips N.V.
  • 10.4 Boston Scientific Corporation
  • 10.5 Johnson & Johnson
  • 10.6 Stryker Corporation
  • 10.7 Sanofi
  • 10.8 Abbott Laboratories
  • 10.9 Leo Pharma A/S
  • 10.10 Novartis AG
  • 10.11 Pfizer Inc.
  • 10.12 Mylan N.V.
  • 10.13 Argon Medical Devices, Inc.
  • 10.14 Medtronic plc
  • 10.15 Teva Pharmaceutical Industries Ltd.
  • 10.16 LifeTech Scientific Corporation
  • 10.17 Bayer AG
  • 10.18 CSL Limited
  • 10.19 Biogenics Inc.

List of Tables

  • Table 1 Global Venous Thromboembolism Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 4 Global Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 5 Global Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 6 Global Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 7 Global Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 8 Global Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 9 Global Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 10 Global Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 11 Global Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 12 Global Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 13 Global Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 14 Global Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 15 Global Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 16 Global Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 17 Global Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 18 Global Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 19 Global Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 20 North America Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 22 North America Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 23 North America Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 24 North America Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 25 North America Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 26 North America Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 27 North America Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 28 North America Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 29 North America Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 30 North America Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 31 North America Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 32 North America Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 33 North America Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 34 North America Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 North America Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 36 North America Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 37 North America Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 38 North America Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 39 Europe Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 41 Europe Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 42 Europe Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 43 Europe Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 44 Europe Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 45 Europe Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 46 Europe Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 47 Europe Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 48 Europe Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 49 Europe Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 50 Europe Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 51 Europe Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 52 Europe Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 53 Europe Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 54 Europe Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 55 Europe Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 56 Europe Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 57 Europe Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 58 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 60 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 61 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 62 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 63 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 64 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 65 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 66 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 67 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 68 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 69 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 70 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 71 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 72 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 73 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 74 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 75 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 76 Asia Pacific Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 77 South America Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 79 South America Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 80 South America Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 81 South America Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 82 South America Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 83 South America Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 84 South America Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 85 South America Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 86 South America Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 87 South America Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 88 South America Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 89 South America Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 90 South America Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 91 South America Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 92 South America Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 93 South America Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 94 South America Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 95 South America Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 96 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 98 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Thrombectomy Devices (2021-2030) ($MN)
  • Table 99 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Inferior Vena Cava Filters (2021-2030) ($MN)
  • Table 100 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Retrievable Filters (2021-2030) ($MN)
  • Table 101 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Permanent Filters (2021-2030) ($MN)
  • Table 102 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Stockings (2021-2030) ($MN)
  • Table 103 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Anticoagulant Medications (2021-2030) ($MN)
  • Table 104 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Compression Pumps (2021-2030) ($MN)
  • Table 105 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 106 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 107 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Deep Vein Thrombosis (2021-2030) ($MN)
  • Table 108 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Pulmonary Embolism (2021-2030) ($MN)
  • Table 109 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 110 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 111 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 112 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 113 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Catheterization Laboratories (2021-2030) ($MN)
  • Table 114 Middle East & Africa Venous Thromboembolism Treatment Market Outlook, By Other End Users (2021-2030) ($MN)